Development of a Necroptosis-related Gene Signature and the Immune Landscape in Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2023 Apr 24

PMID 37095524

Authors

Sipei Nie

Na Ni

Ningxin Chen

Min Gong

Ercui Feng

Jinhui Liu

Qiaoling Liu

Affiliations

Soon will be listed here.

Abstract

Background: Necroptosis is a novel type of programmed cell death distinct from apoptosis. However, the role of necroptosis in ovarian cancer (OC) remains unclear. The present study investigated the prognostic value of necroptosis-related genes (NRGs) and the immune landscape in OC.

Methods: The gene expression profiling and clinical information were downloaded from the TCGA and GTEx databases. Differentially expressed NRGs (DE-NRGs) between OC and normal tissueswere identified. The regression analyses were conducted to screen the prognostic NRGs and construct the predictive risk model. Patients were then divided into high- and low-risk groups, and the GO and KEGG analyses were performed to explore bioinformatics functions between the two groups. Subsequently, the risk level and immune status correlations were assessed through the ESTIMATE and CIBERSORT algorithms. The tumor mutation burden (TMB) and the drug sensitivity were also analyzed based on the two-NRG signature in OC.

Results: Totally 42 DE-NRGs were identified in OC. The regression analyses screened out two NRGs (MAPK10 and STAT4) with prognostic values for overall survival. The ROC curve showed a better predictive ability in five-year OS using the risk score. Immune-related functions were significantly enriched in the high- and low-risk group. Macrophages M1, T cells CD4 memory activated, T cells CD8, and T cells regulatory infiltration immune cells were associated with the low-risk score. The lower tumor microenvironment score was demonstrated in the high-risk group. Patients with lower TMB in the low-risk group showed a better prognosis, and a lower TIDE score suggested a better immune checkpoint inhibitor response in the high-risk group. Besides, cisplatin and paclitaxel were found to be more sensitive in the low-risk group.

Conclusions: MAPK10 and STAT4 can be important prognosis factors in OC, and the two-gene signature performs well in predicting survival outcomes. Our study provided novel ways of OC prognosis estimation and potential treatment strategy.

Citing Articles

Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer.

Xu W, Sang S, Wang J, Guo S, Zhang X, Zhou H Front Immunol. 2024; 15:1452946.

PMID: 39355254 PMC: 11442270. DOI: 10.3389/fimmu.2024.1452946.

Genetic alterations in the neuronal development genes are associated with changes of the tumor immune microenvironment in pancreatic cancer.

Mu K, Fu J, Gai J, Ravichandran H, Zheng L, Sun W Ann Pancreat Cancer. 2024; 6(10).

PMID: 38495381 PMC: 10942730. DOI: 10.21037/apc-23-13.

Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.

Huan Q, Cheng S, Ma H, Zhao M, Chen Y, Yuan X J Cell Mol Med. 2023; 28(1):e18021.

PMID: 37994489 PMC: 10805490. DOI: 10.1111/jcmm.18021.

Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma.

Geng Y, Sun Y, Song H, Miao Q, Wang Y, Qi J Clin Cosmet Investig Dermatol. 2023; 16:1623-1639.

PMID: 37396711 PMC: 10312339. DOI: 10.2147/CCID.S410723.

Editorial: Molecular landscapes of human papillomavirus-related squamous cell carcinoma.

Shen Y, Liu J Front Oncol. 2023; 13:1215142.

PMID: 37324015 PMC: 10264761. DOI: 10.3389/fonc.2023.1215142.

References

Carithers L, Moore H . The Genotype-Tissue Expression (GTEx) Project. Biopreserv Biobank. 2015; 13(5):307-8. PMC: 4692118. DOI: 10.1089/bio.2015.29031.hmm. View

Goldman M, Craft B, Hastie M, Repecka K, McDade F, Kamath A . Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38(6):675-678. PMC: 7386072. DOI: 10.1038/s41587-020-0546-8. View

Cheng J, Yao M, Zhu Q, Wu X, Zhou J, Tan W . Silencing of stat4 gene inhibits cell proliferation and invasion of colorectal cancer cells. J Biol Regul Homeost Agents. 2015; 29(1):85-92. View

Li S, Sheng B, Zhao M, Shen Q, Zhu H, Zhu X . The prognostic values of signal transducers activators of transcription family in ovarian cancer. Biosci Rep. 2017; 37(4). PMC: 5518537. DOI: 10.1042/BSR20170650. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Galluzzi L, Kroemer G . Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008; 135(7):1161-3. DOI: 10.1016/j.cell.2008.12.004. View

Hernandez L, Kim M, Noonan A, Sagher E, Kohlhammer H, Wright G . A dual role for Caspase8 and NF-B interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival. Cell Death Discov. 2017; 1:15053. PMC: 5198842. DOI: 10.1038/cddiscovery.2015.53. View

Najafov A, Chen H, Yuan J . Necroptosis and Cancer. Trends Cancer. 2017; 3(4):294-301. PMC: 5402749. DOI: 10.1016/j.trecan.2017.03.002. View

Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M . New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2018; 47(D1):D590-D595. PMC: 6324070. DOI: 10.1093/nar/gky962. View

10.

Brachova P, Mueting S, Carlson M, Goodheart M, Button A, Mott S . TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 2014; 46(2):607-18. PMC: 4277253. DOI: 10.3892/ijo.2014.2747. View

11.

Kunde S, Rademacher N, Tzschach A, Wiedersberg E, Ullmann R, Kalscheuer V . Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients. Hum Genet. 2013; 132(4):461-71. DOI: 10.1007/s00439-012-1260-5. View

12.

Mei S, Meyer C, Zheng R, Qin Q, Wu Q, Jiang P . Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer. Cancer Res. 2017; 77(21):e19-e22. PMC: 5826647. DOI: 10.1158/0008-5472.CAN-17-0327. View

13.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

14.

Tan Y, Sementino E, Cheung M, Peri S, Menges C, Kukuyan A . Somatic Epigenetic Silencing of Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. Clin Cancer Res. 2020; 27(4):1200-1213. PMC: 7887036. DOI: 10.1158/1078-0432.CCR-18-3683. View

15.

Stoll G, Ma Y, Yang H, Kepp O, Zitvogel L, Kroemer G . Pro-necrotic molecules impact local immunosurveillance in human breast cancer. Oncoimmunology. 2017; 6(4):e1299302. PMC: 5414877. DOI: 10.1080/2162402X.2017.1299302. View

16.

Strilic B, Yang L, Albarran-Juarez J, Wachsmuth L, Han K, Muller U . Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016; 536(7615):215-8. DOI: 10.1038/nature19076. View

17.

Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y . Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021; 1875(2):188503. DOI: 10.1016/j.bbcan.2021.188503. View

18.

He Y, Fang L, Hu D, Chen S, Shen S, Chen K . Necroptosis-associated long noncoding RNAs can predict prognosis and differentiate between cold and hot tumors in ovarian cancer. Front Oncol. 2022; 12:967207. PMC: 9366220. DOI: 10.3389/fonc.2022.967207. View

19.

Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C . RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Science. 2015; 350(6258):328-34. PMC: 4651449. DOI: 10.1126/science.aad0395. View

20.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View